diaDexus, Inc. Share Price OTC Bulletin Board

DDXS

US25245P1066

Pharmaceuticals

OTC Markets Traded

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

17/21/17	Diadexus, Inc. Went Out of Business	CI
08/18/08	Motion for Asset Sale Approved for Diadexus, Inc.	CI

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	49.2T 42.44T 39.02T 36.73T 69.02T 46.43L 69.6T 5L 2L 22.79L 2L 2L 78.83L	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	52.9L 45.64L 41.96L 39.49L 74.21L 50Cr 74.84L 4.97Cr 1.94Cr 25Cr 1.99Cr 1.94Cr 85Cr	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/21/17	Diadexus, Inc. Went Out of Business	CI
08/18/08	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/18/09	Motion for Asset Sale Filed by Diadexus, Inc.	CI
01/16/01	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/16/29	Motion for Asset Sale Approved for Diadexus, Inc.	CI
29/16/29	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
20/16/20	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/16/07	Motion for Asset Sale Filed by Diadexus, Inc.	CI
07/16/07	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/16/13	Diadexus, Inc. Filed for Bankruptcy	CI
10/16/10	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/16/23	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
30/16/30	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ULTRAGENYX PHARMACEUTICAL INC.	+8.29%	+17.15%	-26.60%	-44.26%	264.23Cr
SAREPTA THERAPEUTICS, INC.	+7.48%	+12.24%	-21.34%	-87.00%	179.06Cr
BIONOTE, INC.	-2.66%	+0.64%	-7.77%	+1.93%	32Cr
DK LIFE SCIENCE CO., LTD.	+0.69%	+8.91%	-36.88%	-	6.2Cr
Average	+3.45%	+8.01%	-23.15%	-43.11%	120.31Cr
Weighted average by Cap.	+7.17%	+13.94%	-23.53%	-57.28%

	2014	2015
Net sales	2.61Cr 2.25Cr 2.07Cr 1.95Cr 3.66Cr 246.43Cr 3.69Cr 25Cr 9.56Cr 120.94Cr 9.8Cr 9.59Cr 418.4Cr	1.79Cr 1.54Cr 1.42Cr 1.34Cr 2.51Cr 168.78Cr 2.53Cr 17Cr 6.54Cr 83Cr 6.71Cr 6.57Cr 286.56Cr
Net income	-84.67L -73.04L -67.16L -63.21L -1.19Cr -80Cr -1.2Cr -7.96Cr -3.1Cr -39Cr -3.18Cr -3.11Cr -135.67Cr	-71.66L -61.82L -56.84L -53.5L -1.01Cr -68Cr -1.01Cr -6.74Cr -2.62Cr -33Cr -2.69Cr -2.63Cr -114.82Cr
Net Debt	-2L -2L -2L -1L -3L -1.87Cr -3L -18.61L -7L -91.71L -7L -7L -3.17Cr	52.41L 45.21L 41.57L 39.13L 73.52L 49Cr 74.14L 4.93Cr 1.92Cr 24Cr 1.97Cr 1.93Cr 84Cr

diaDexus, Inc. Share Price OTC Bulletin Board

Stocks

DDXS

US25245P1066

Pharmaceuticals

Valuation: diaDexus, Inc.

Latest news : diaDexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile